Similar articles

• Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.

  Yoon DK, Park HS, Park JY. Yoon DK, et al. J Urol. 2010 Nov;184(5):2214-5; author reply 2215. doi: 10.1016/j.juro.2010.06.128. Epub 2010 Sep 22. J Urol. 2010. PMID: 20864135 No abstract available.
• Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.

  Wagner MD, Daneshmand S, Sokoloff M, Barry JM. Wagner MD, et al. J Urol. 2007 Jun;177(6):2396; author reply 2396-7. doi: 10.1016/j.juro.2007.01.172. J Urol. 2007. PMID: 17509368 No abstract available.
• Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. Terris, K. Walker, C. L. Amling, P. R. Carroll and M. R. Cooperberg J Urol 2016;196:1408-1414.

  Heilbrun LK, Powell IJ. Heilbrun LK, et al. J Urol. 2018 Jan;199(1):305-306. doi: 10.1016/j.juro.2017.08.102. Epub 2017 Sep 27. J Urol. 2018. PMID: 28961419 No abstract available.
• The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer.

  Skolarus TA, Wolin KY, Grubb RL 3rd. Skolarus TA, et al. Nat Clin Pract Urol. 2007 Nov;4(11):605-14. doi: 10.1038/ncpuro0944. Nat Clin Pract Urol. 2007. PMID: 17982437 Review.
• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

  Lilja H, Ulmert D, Vickers AJ. Lilja H, et al. Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351. Nat Rev Cancer. 2008. PMID: 18337732 Review.